Expired activity
Please go to the PowerPak homepage and select a course.

Immune Checkpoint Inhibitors as First-Line Therapy for Metastatic Melanoma: Update for Oncologists, Oncology Pharmacists, and Oncology Nurses

Jointly Provided by Postgraduate Healthcare Education, LLC (PHE) and Postgraduate Institute for Medicine (PIM).

This activity is supported by an independent educational grant from Bristol Myers Squibb.


Jaime E. Anderson, PharmD, BCOP, CMQ
Manager, Clinical Pharmacy Services
University of Illinois at Chicago
Clinical Pharmacy Specialist
Melanoma Medical Oncology
Division of Pharmacy
University of Texas MD Anderson Cancer Center
Houston, TX

Yana G. Najjar, MD
Assistant Professor of Medicine
Research Physician—Melanoma
Hematology-Oncology, Department of Medicine
UPMC Hillman Cancer Center
Pittsburgh, PA

Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP, APHN- BC
Family Nurse Practitioner, Melanoma/Sarcoma Medical Oncology Group
APN Manager: Melanoma/ Cutaneous Oncology & Phase 1 Research
New York University Langone Perlmutter Cancer Center
New York, New York


Dr. Anderson has disclosed that she has no relevant affiliations or financial relationships with a commercial interest to disclose.

Dr. Najjar has disclosed that she has received consulting fees from Array Biopharma, Intervenn Bio, Merck & Co., and Novartis; has institutional research funding from Bristol Myers Squibb, Merck & Co., Pfizer and Replimmune; and is a member of the Immunocore and Pfizer Speaker's Bureaus.

Ms. Madden has disclosed that she received consulting fees from Novartis.

The clinical reviewer, Megan May, PharmD, BCOP has disclosed that she has no relevant affiliations or financial relationships with a commercial interest to disclose.

Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

The PIM planners and others have nothing to disclose.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0430-9999-22-093-H01-P
Credits: 1.5 hour (0.15 ceu)

Joint Accreditation statement
Joinly Accredited Provider

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Postgraduate Healthcare Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Type of Activity: Application
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 90 minutes


October 20, 2022


April 20, 2023


Oncologists, Oncology Pharmacists, Nurses and Nurse Practitioners


During the period October 20, 2022 to April 20, 2023, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


The goal of this educational activity is to educate oncologists, oncology pharmacists, and oncology nurses on clinical evidence for the use of immune checkpoint inhibitors as first-line therapy for metastatic melanoma including current agents, monotherapy and combination regimens, newly approved combination regimens, adverse drug effects, and emerging therapies, which will serve to optimize patient outcomes and quality of life.


Upon completion of this program, participants should be better able to:

  • Identify immunotherapy agents and regimens approved and optimal for first-line treatment of metastatic melanoma.
  • Indicate factors that impact selection of first-line agents and regimens.
  • Explain the basis of non-response to immunotherapy agents and regimens in use for metastatic melanoma and rational strategies to overcome this non-response.
  • Formulate approaches for identifying and mitigating toxicities associated with immunotherapy to optimize treatment outcomes and patient safety.


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Postgraduate Institute for Medicine (PIM), or Bristol Myers Squibb. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.